AN2 Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Eric Easom
Chief executive officer
US$3.3m
Total compensation
| CEO salary percentage | 17.2% |
| CEO tenure | 5yrs |
| CEO ownership | 4.1% |
| Management average tenure | 5yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Nov 21
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?
Jul 04Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$66m |
| Dec 31 2023 | US$3m | US$575k | -US$65m |
| Sep 30 2023 | n/a | n/a | -US$60m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$49m |
| Dec 31 2022 | US$3m | US$481k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$40m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$2m | US$377k | -US$28m |
Compensation vs Market: Eric's total compensation ($USD3.34M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
CEO
Eric Easom (56 yo)
5yrs
Tenure
US$3,342,848
Compensation
Mr. Eric E. Easom is Co-founder of AN2 Therapeutics, Inc. and has been its CEO, President & Director from November 19, 2019 and is its Chairman of the Board since June 2024. He served as Senior Director of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5yrs | US$3.34m | 4.06% $ 1.3m | |
| Co-Founder & Chairman of the Board | 7.5yrs | US$179.64k | 1.69% $ 534.3k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 5yrs | US$1.52m | 0.010% $ 3.3k | |
| Co-Founder & Senior Clinical Advisor | no data | no data | no data | |
| Co-Founder & Head of Biology | no data | no data | no data | |
| Chief Legal Officer | 2.2yrs | US$1.66m | no data | |
| Chief Development Officer | 5yrs | no data | 0.0025% $ 778.2 | |
| Chief Strategy Officer | no data | no data | 0.026% $ 8.2k |
5.0yrs
Average Tenure
60.5yo
Average Age
Experienced Management: ANTX's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5yrs | US$3.34m | 4.06% $ 1.3m | |
| Co-Founder & Chairman of the Board | 7.5yrs | US$179.64k | 1.69% $ 534.3k | |
| Independent Director | 2.8yrs | US$145.64k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$153.14k | 0% $ 0 | |
| Lead Independent Director | 2.5yrs | US$142.14k | 0% $ 0 | |
| Independent Director | 5yrs | US$146.14k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$157.14k | 0% $ 0 | |
| Independent Director | 5yrs | US$145.64k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$145.64k | 0.076% $ 24.2k |
4.8yrs
Average Tenure
60yo
Average Age
Experienced Board: ANTX's board of directors are considered experienced (4.8 years average tenure).